Results 121 to 130 of about 432,722 (348)
Molecular Oncology, EarlyView.The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat +18 more
wiley +1 more source
Next‐generation proteomics improves lung cancer risk prediction
Molecular Oncology, EarlyView.This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
RANGE AND CHARACTERISTICS TRANSMUCOSAL DOSAGE FORMS
Разработка и регистрация лекарственных средств, 2019 Currently, one of the promising methods of taking medications are instant formulations (in particular, medicinal films), which have a number of advantages over traditional dosage forms.
N. V. Shestakov +3 more
doaj
Solution for Solution for Infusion Dosage Form [PDF]
, 2020 National Cancer Institute
openalex +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Inkjet printing of oral dosage forms to solubilize BCS Class II drugs [PDF]
, 2018 Oral drug delivery remains the preferred method of administration but BCS Class II drugs are not ideally suited to this due to their inherent poor solubility.
Florence, Alastair J. +2 more
core
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source